FMS-like tyrosine kinase 3 ligand
FMS-like tyrosine kinase 3 ligand (also known as FLT3L) is a growth factor that regulates the development of hematopoietic cells, the cells that give rise to all other blood cells. It is a member of a small family of growth factors that includes stem cell factor (SCF) and colony-stimulating factor 1 (CSF-1).
FLT3L binds to and activates the FMS-like tyrosine kinase 3 (FLT3) receptor, a class III receptor tyrosine kinase. This binding and activation leads to the proliferation, differentiation, and survival of hematopoietic cells. FLT3L is essential for the development of the immune system and is particularly important for the generation of dendritic cells, which are key regulators of immune responses.
FLT3L is produced by various cell types, including T cells and bone marrow stromal cells. It is also found in the plasma and serum of healthy individuals. The level of FLT3L in the blood can be used as a biomarker for certain diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
FLT3L has been used in clinical trials as a therapeutic agent to boost the immune response in cancer patients. It has also been used to enhance the efficacy of cancer vaccines.
Structure[edit | edit source]
FLT3L is a soluble protein that is secreted by cells. It is composed of a single polypeptide chain that is folded into a compact, globular structure. The protein has a molecular weight of approximately 30 kilodaltons.
Function[edit | edit source]
FLT3L binds to the FLT3 receptor on the surface of hematopoietic cells. This binding activates the receptor, triggering a cascade of intracellular signaling events that lead to the proliferation, differentiation, and survival of the cells.
Clinical significance[edit | edit source]
The level of FLT3L in the blood can be used as a biomarker for certain diseases. Elevated levels of FLT3L have been observed in patients with AML and MDS. In these patients, the high level of FLT3L is thought to reflect an increased demand for hematopoietic cells.
FLT3L has been used in clinical trials as a therapeutic agent to boost the immune response in cancer patients. It has been shown to increase the number of dendritic cells, enhancing the body's ability to mount an immune response against cancer cells.
See also[edit | edit source]
- FMS-like tyrosine kinase 3
- Hematopoietic stem cell
- Dendritic cell
- Acute myeloid leukemia
- Myelodysplastic syndromes
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
